$HGTY

Hagerty (HGTY) director purchases 15,000 Class A common shares

Hagerty, Inc. director Anthony J. Kuczinski recently purchased 15,000 shares of the company’s Class A common stock on the open market. The transaction, executed at a weighted average price of $10.72 per share, increased his direct holdings to 43,277 shares. This insider trade is considered a positive signal for the company.

Original reporting
Published Mar 4, 2026, 9:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 4, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$HGTY
Bullish
high confidence
Mentioned
$HGTY
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$HGTYBullishMed
01

Why it matters

The insider purchase signals internal confidence, which may positively influence investor sentiment and stock price.

02

Market read

The insider transaction is relevant for traders interested in Hagerty (HGTY), especially those focusing on insider activity as a sentiment indicator.

03

What to watch

Potential for insider buying to be motivated by personal reasons unrelated to company fundamentals; need to corroborate with other positive indicators.

Timing: Immediate, as the transaction occurred recently.

Background

Hagerty, Inc. is a specialty insurance company focusing on classic cars and collectibles.

Company-level read

Ticker impact

$HGTYBullishHigh confidence
Context

The insider purchase by a director indicates potential positive sentiment towards Hagerty (HGTY).

Expected impact

Moderate upward price movement expected in the short to medium term.

Evidence & confidence

Insider buying is generally viewed as a strong positive signal, especially when executed at a significant volume. The purchase increases the insider's holdings and reflects internal confidence, which can influence investor perception.

Market effects

Potential positive impact on the insurance and financial services sectors, where Hagerty operates.

Limited, as the news pertains to a U.S.-based company's insider activity.

Negligible, as this is a company-specific insider transaction.

Counterpoint

Insider buying does not guarantee future stock performance; external factors or broader market conditions could negate the positive signal.

Key entities

  • Anthony J. Kuczinski

    Director of Hagerty, Inc.

  • Hagerty, Inc.

    A specialty insurance provider focusing on classic cars and collectibles.

Related articles

$HGTYMedAI 9/10

Hagerty Reports Second Quarter 2026 Results

Hagerty, Inc. (NYSE: HGTY) reported second quarter and first-half 2026 results, citing record member and premium growth and an increased 2026 outlook. First-half written premium rose 19% to $713 million and earned premium rose 42% to $492 million. Net loss was $5 million, including $153 million of Markel Fronting transitional costs. Adjusted EBITDA rose 32% to $160 million; 2026 guidance: written premium growth 16% to 17%, net income $18 to $30 million, and adjusted EBITDA $270 to $280 million.

$HGTYHigh

Hagerty, Inc. (HGTY): Results of Operations and Financial Condition

Hagerty, Inc. (HGTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. STOCKHOLDER LETTER Q2 2026 Every summer, Hagerty Drivers Club magazine names its Road of the Year. This year the pick is Pennsylvania State Route 144, a little-known run through the north central part of the state. Members wait for that issue because it hands them somewhere new t

$HGTYMed

Bike broker Bennetts changes hands again as Hagerty swoops

Hagerty, a NYSE-listed collector vehicle insurer, will buy motorbike broker Bennetts from Lucida Group for £34m, with closing expected in Q3. The acquisition will fold Bennetts into Hagerty UK and is expected to triple Hagerty’s UK revenue to about £25m. Bennetts was acquired by Lucida in 2021 after Ardonagh bought it in 2020.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.